Gynion is a Women’s Health startup with a mission to offer millions of women worldwide safe, effective, and affordable in-office therapies helping to avoid unnecessary hysterectomies and improve and save lives.

Gynion is developing a therapeutic platform for multiple indications in gynecology and dermatology.

ClarablexTM is a topical gel for deep tissue ablation. It is a treatment for multiple indications in gynecology and dermatology, including cervical intraepithelial neoplasia (CIN) caused by human papillomavirus (HPV) to prevent cervical cancer. In the pre-clinical trial, Clarablex demonstrates results that are expected to be sufficient to treat CIN2+.

MenorrxTM is a therapy for Heavy Menstrual Bleeding (HMB). In the pre-clinical trial, Menorrx shows promise to be a safe and effective non-invasive in-office treatment. It is simpler, easier to use, and will cost significantly less than the alternatives. Because of the high cost and clinical limitations of the available options, millions of women receive no treatment or are compelled to undergo a hysterectomy. Menorrx presents a substantial opportunity to change that both in developed markets and low-resource countries.

Management Team

Oleg Shikhman

Founder & CEO

Victoria Shikhman, ND

Founder & interim VP of Clinical Research
Doctor of Naturopathic Medicine

Steven Goldstein, MD

Professor of OBGYN at NYU Medical Center

Nicole Shugrue

Market Advisor

Julie Gionfriddo

Business Development Advisor

Dana Dunn

Regulatory Advisor

Clinical Advisors

Malcolm Munro, MD

Professor of OBGYN, UCLA
FIGO Menstrual Disorders Committee

Amy Garcia, MD

Medical Director, The Center for Women’s Surgery

Paul Blumenthal, MD

Professor of OBGYN,
Stanford University

Tulay Okman Kilic, MD

Professor of OBGYN
Istambul, Turkey

Juan Canela Oleaga, MD

Director of OBGYN Surgery
Dominical Republic

Contact Us

Oleg Shikhman, CEO
Gynion LLC